NEWS SEARCH ANALYSIS INSIGHT

360° SearchNetwork Hot Spots Trends

Advanced Search Options >>

Saturday, November 21, 2009 9:16 AM

Phase III Trial

Type: Keyphrase

Name: Phase III Trial

First Reported 11/19/2009 - Updated 11/19/2009 - 1 Documents (in Health)

Food and Drug Administration

AstraZeneca Applies To the FDA For Its New Angina and Heart Attack Treatment

AstraZenec (LSE: AZN) announced the submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for the drug ticagrelo. The application is for an investigational oral antiplatelet treatment for patients with acute coronary ... [Proactiveinvestors United Kingdom RSS feed - 11/19/2009]

Entities: Food and Drug Administration, Heart Attack, AstraZeneca PLC

First Reported 11/19/2009 - Updated 11/19/2009 - 1 Documents (in Medicine)

Genzyme Corporation

Genzyme-Isis’ mipomersen cuts cholesterol by 25% in Phase III

A pivotal Phase III trial with mipomersen, under development by Genzyme Corp and Isis Pharmaceuticals for high-risk cardiovascular patients who cannot achieve target cholesterol levels with statins and/or other lipid-lowering therapies, has shown the ... [Pharma Times - 11/19/2009]

Entities: Placebo, Phase III Trial, Genzyme, Enzyme, Genzyme Corporation

First Reported 11/19/2009 - Updated 11/19/2009 - 1 Documents

Clinical Data starts late-stage trial of Stedivaze

A Phase III trial comparing Clinical Data's cardiac stress-testing agent Stedivaze with adenosine is under way. The two-year trial, which involves 750 patients, will also assess adverse effects associated with the agents.Mass High Tech| 11/18More from ... [SmartBrief - 11/19/2009]

Entities: Clinical Data Inc, Molecular Imaging, Nuclear Medicine

First Reported 20 hours ago - Updated 20 hours ago - 1 Documents (in Health)

Pfizer Inc

Encouraging results for Merck heart drug

Merck's investigational heart drug anacetrapib has shown encouraging results in a phase IIb study.Patients receiving higher doses experienced benefits on both 'good' (HDL-C) and 'bad' (LDL-C) cholesterol levels two months after they stopped taking it ... [Pharmafocus - 20 hours ago]

Entities: Pfizer Inc, Lipitor, efficacy

First Reported 16 hours ago - Updated 16 hours ago - 1 Documents (in Biology)

An Undervalued Biotech

Antisoma is fully funded and has three potential blockbusters.I have a soft spot for life sciences companies that combine strong balance sheets with products facing the final hurdle (phase III trials). In the last year I have looked at Renova (LSE: RNVO), ... [Motley Fool UK - 16 hours ago]

Entities: Antisoma plc, Biotechnology, Renova, Lung Cancer

First Reported 14 hours ago - Updated 14 hours ago - 1 Documents

Study: Actemra better than placebo in late-stage trial

More patients who took Roche Holding's Actemra had reduced signs and symptoms of systemic onset juvenile idiopathic arthritis than those given placebo after 12 weeks of treatment in a Phase III trial. The finding adds to evidence of Actemra's efficacy ... [SmartBrief - 14 hours ago]

Entities: Placebo, Phase III Trial, Rheumatoid Arthritis

First Reported 2 hours ago - Updated 2 hours ago - 1 Documents (in Medicine)

Clinical Data initiates enrollment in Phase III cardiac stress testing trial

Clinical Data has enrolled the first patient in its initial Phase III trial of Stedivaze, a potential vasodilator for use in cardiac stress testing.The study will evaluate the safety and efficacy of Stedivaze for use as a pharmacologic stress agent in ... [Individual.com - 2 hours ago]

Entities: Clinical Data Inc, Phase III Trial, Induction

First Reported 11/18/2009 - Updated 11/18/2009 - 4 Documents

Clinical Data commences patient enrollment in Stedivaze Phase III trial

Clinical Data, Inc. (NASDAQ: CLDA) today announced that it has enrolled the first patient in its initial Phase III trial of Stedivaze™, a potential best-in-class vasodilator for use in cardiac stress testing. The study will evaluate the safety and efficacy ... [News-Medical.Net - 11/18/2009]

Entities: Clinical Data Inc, Phase III Trial, Tolerance, bolus, perfusion

First Reported 11/17/2009 - Updated 11/17/2009 - 4 Documents

Market Report -- In Play (CERS)

Cerus receives FDA Blood Products Advisory Committee guidance for proposed INTERCEPT Blood System Ph. III trial design Co announces the FDA's Blood Products Advisory Committee rendered a positive opinion on the proposed hemostatic efficacy and safety ... [Briefing.com via MSN Money - 11/17/2009]

Entities: Cerus Corporation, Blood Products, Food and Drug Administration, Phase III Trial

First Reported 11/16/2009 - Updated 11/16/2009 - 3 Documents (in Medicine)

Additional data from Aegerion Pharmaceuticals' ongoing lomitapide Phase III trial

Aegerion Pharmaceuticals, Inc., a biopharmaceutical company focused on the treatment of cardiovascular and metabolic disease, today announced additional data from its ongoing Phase III trial involving its lead cholesterol management compound, lomitapide ... [News-Medical.Net - 11/16/2009]

Entities: Aegerion Pharmaceuticals Inc, Phase III Trial, hepatic, Tolerance

First Reported 11/18/2009 - Updated 11/18/2009 - 2 Documents (in Health)

Poniard drug OK in mid-stage cancer study

Poniard Pharmaceuticals Inc., which stumbled with its cancer drug picoplatin in a Phase III trial, hit the main goal of a mid-stage metastatic colorectal cancer study using the chemotherapy agent, the company said Wednesday.The South San Francisco company ... [Biz Journals - 11/18/2009]

Entities: Chemotherapy, Phase III Trial, Eloxatin, Poniard Pharmaceuticals Inc

First Reported 11/18/2009 - Updated 11/18/2009 - 2 Documents

Advanced BioMedical Finds Partner for New Use of Medical Device

Advanced BioMedical Technologies (ABMT.OB) said its operating subsidiary, Shenzhen Changhua Biomedical Engineering Co. (ABT-Changhua), has signed a cooperative agreement to develop its Polyamide (PA) bio-absorbable material in new applications. Together ... [Seeking Alpha - 11/18/2009]

Entities: Guangdong Pharmaceutical University, Biomedical Engineering, Phase III Trial

Quotes

...Heart Journal in February 2009,' said Yale Mitchel, Merck Research Laboratories' vice president of cardiovascular disease clinical research. "A phase III trial, titled DEFINE, is ongoing to further evaluate the safety and efficacy of anacetrapib in patients with coronary heart disease and will provide important information on this compound." Three years ago Pfizer was forced to abandon its own late-stage CETP inhibitor following serious safety concerns...

Encouraging results for Merck heart drug [Pharmafocus - 20 hours ago]

...from two Japanese studies and is thus an incremental positive for the drug,' said Helvea analysts Karl-Heinz Koch and Odile Rundquist in a note. "However, with the patient population (for sJIA) limited to 15,000 patients in the developed world the sales potential is small, at less than $200 million" they said...

UPDATE 2-Roche's Actemra successful in arthritis study [Interactive Investor International - 20 hours ago]

...as a highly effective and well-tolerated treatment for children suffering from sJIA' said William M Burns, CEO of Roche's Pharmaceuticals Division. "This is a particularly debilitating disease affecting the entire body in which morbidity is high and there is much need for new treatment options in this area. These results are encouraging and should bring hope to those children affected by this difficult to treat disease." The TENDER study is the first global phase III trial on ACTEMRA, and it confirms earlier data from two Japanese studies...

ACTEMRA Improves Signs and Symptoms in Children with Systemic Onset Juvenile Idiopathic Arthritis ... [CHUGAI PHARMACEUTICAL - 22 hours ago]

"We are extremely pleased with the progress of the Phase III trial enrollment for CM-AT and are continuing to move forward with the other sites in the study across the country" said Dr. Joan Fallon, Curemark founder and CEO...

Curemark begins enrolling patients in Phase III clinical trials for CM-AT [News-Medical.Net - 11/20/2009]

More Content

sort by: Date \| Relevance
Clinical Data initiates enrollment in Phase III... [Individual.com - 2 hours ago]
FDA approves sNDA for pediatric autism drug ABI... [News-Medical.Net - 4 hours ago]
Safeguard Scientifics, Inc. Q3 2009 Earnings Ca... [Seeking Alpha - 9 hours ago]
Roche's ACTEMRA Has Met Its Primary Endpoint In... [PharmaceuticalProcessing - 12 hours ago]
What Are Clinical Trials? [Cancer Consultants - 13 hours ago]
New Blood Thinner Reduces Death, Stent Thrombosis [Diagnostic & Invasive Cardiology - 14 hours ago]
Study: Actemra better than placebo in late-stag... [SmartBrief - 14 hours ago]
Panel: FluBlok Safety, Efficacy Data Insufficie... [BioWorld - 15 hours ago]
An Undervalued Biotech [Motley Fool UK - 16 hours ago]
BMS splits off Mead Johnson, signs potential $1... [Drug Discovery News - 16 hours ago]
Noble Insight raises ImmuPharma valuation to 23... [Proactive Investors.co.uk - 18 hours ago]
BioMed News Bytes: AstraZeneca, Delcath, Unilife [Seeking Alpha - 18 hours ago]
Encouraging results for Merck heart drug [Pharmafocus - 20 hours ago]
UPDATE 2-Roche's Actemra successful in arthriti... [Interactive Investor International - 20 hours ago]
ACTEMRA Improves Signs and Symptoms in Children... [CHUGAI PHARMACEUTICAL - 22 hours ago]
Noble Insight raises ImmuPharma valuation to 23... [Proactiveinvestors United Kingdom RSS feed - 22 hours ago]
Data from second positive pivotal study of PSD5... [News-Medical.Net - 11/20/2009]
Curemark begins enrolling patients in Phase III... [News-Medical.Net - 11/20/2009]
TopAbstracts in Ovarian Cancer 11/18/2009 [Doctors Guide - 11/19/2009]
Cancer Therapies - Global Market Opportunities [Pharmacy Choice - 11/19/2009]
Clinical Data starts late-stage trial of Stedivaze [SmartBrief - 11/19/2009]
BioMed News Bytes: AstraZeneca, Delcath, Unilif... [SocialPicks - 11/19/2009]
Genzyme-Isis’ mipomersen cuts cholesterol by 25... [Pharma Times - 11/19/2009]
Research and Markets: Cancer Therapies - Global... [Business Wire UK - 11/19/2009]
Pivotal study for PSD502 -- the first potential... [EurekAlert! - 11/19/2009]
Oral-lyn vs. Afresa: How Generex Will Beat Mann... [Seeking Alpha - 11/19/2009]
Jennerex and Lee's to Develop New Cancer Drug i... [Pharmaceutical Technology - 11/19/2009]
Failed anti-depressant flibanserin reborn as fe... [In-Pharmatechnologist - 11/19/2009]
No Relief for Genzyme as APB Failure Dents Rena... [BioWorld - 11/19/2009]
AstraZeneca Applies To the FDA For Its New Angi... [Proactiveinvestors United Kingdom RSS feed - 11/19/2009]

Blogs

sort by: Date \| Relevance
BioMed News Bytes: AstraZeneca, Delcath, Unilife [Healthcare Sector and Stocks Analysis from Seek ... - 19 hours ago] Mike Havrilla submits:On 11/19/09, AstraZeneca (NYSE: AZN) announced the submission of a New Drug Application (NDA) to the FDA for ticagrelor, an investigational ...
BioMed News Bytes: AstraZeneca, Delcath, Unilife [Biotech Sector and Stocks Analysis from Seeking ... - 19 hours ago] Mike Havrilla submits:On 11/19/09, AstraZeneca (NYSE: AZN) announced the submission of a New Drug Application (NDA) to the FDA for ticagrelor, an investigational ...
Poniard Pharmaceuticals' Gamble Doesn't Pay Off [Healthcare Sector and Stocks Analysis from Seek ... - 11/18/2009] EP Vantage submits:Poniard Pharmaceuticals (PARD) on Monday stared into the abyss of disappointment. Shares in the US company lost three quarters of their value ...
Advanced BioMedical Finds Partner for New Use o... [Healthcare Sector and Stocks Analysis from Seek ... - 11/18/2009] ChinaBio Today submits: Advanced BioMedical Technologies (ABMT.OB) said its operating subsidiary, Shenzhen Changhua Biomedical Engineering Co. (ABT-Changhua), has ...
Merck’s Dick Clark Has Opportunities, but All A... [WSJ.com: Deal Journal - 11/16/2009] Jacob Plieth, of Dow Jones Investment Banker, reports: So Richard Clark is on the hunt. The Merck CEO said early this month that he is looking to acquire biotechnology ...

Change Password

Log in to Silobreaker

Advanced Search Options

Phase III Trial